Emricasan (254750-02-2) is a liver-targeted antiapoptotic pan-caspase inhibitor.1,2 It has been investigated as a hepatoprotective agent in the treatment of liver ischemia3 and NASH/NAFLD liver injury4,5. Emricasan protected SNB-19 cells against cell death induced by Zika virus strains MR766, FSS13025, and PRVABC59.6 Emricasan improves the viability of hPSCs and their differentiated progeny when used in a small molecule cocktail (CEPT) containing chroman 1 (Cat# 10-4912), polyamines, and trans-ISRIB (Cat# 10-1539).7
References/Citations:
- Linton et al. (2005), First-in-class Pan Caspase Inhibitor for the Treatment of Liver Disease; J. Med. Chem., 48 6779
- Hoglen et al. (2004), Characterization of IDN-6556 (3-{2-(2-tert-Butylphenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor; J. Pharmacol. Exp. Ther., 309 634
- Hoglen et al. (2007), A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia; Liver Transpl., 13 361
- Barreyro et al. (2015), The pan-caspase inhibitor Emricasan (IDN-5665) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis; Liver Int., 35 953
- Frenette et al. (2019), Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo; Clin. Gastroenterol. Hepatol., 17 774
- Xu et al. (2016), Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen; Nat. Med., 22 1101
- Chen et al. (2021), A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells; Nat. Methods, 18 528
